{
    "clinical_study": {
        "@rank": "94000", 
        "arm_group": [
            {
                "arm_group_label": "Healthy Volunteers", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Mild Renal Impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Moderate renal impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Severe renal impairment", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with renal impairment are the target population for PF-04634817. The clearance\n      mechanism of this drug means that exposure may be increased in subjects with renal\n      impairment. This study will investigate the effect of the drug in subjects with varying\n      degrees of renal impairment. Pharmacokinetics, safety and toleration will be assessed."
        }, 
        "brief_title": "PF-04634817 Renal Impairment Study", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Insufficiency", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female (non child bearing potential aged 18-75 years\n\n          -  Documented renal impairment (mild, moderate or severe using Cockcroft-Gault equation)\n             or matched healthy volunteers (age, weight and gender)\n\n        Exclusion Criteria:\n\n          -  Subjects with acute renal failure\n\n          -  Subjects receiving, or likely to receive, CYP450 3A4 inhibitors\n\n          -  Abnormal ECG at screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791855", 
            "org_study_id": "B1261008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Healthy Volunteers", 
                "description": "Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)", 
                "intervention_name": "PF-04634817", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Mild Renal Impairment", 
                "description": "Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)", 
                "intervention_name": "PF-04634817", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moderate renal impairment", 
                "description": "Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)", 
                "intervention_name": "PF-04634817", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Severe renal impairment", 
                "description": "Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)", 
                "intervention_name": "PF-04634817", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Subjects with Renal Impairment", 
            "healthy"
        ], 
        "lastchanged_date": "October 17, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1261008&StudyName=PF-04634817%20Renal%20Impairment%20Study"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Deland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Single Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04634817", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }, 
            {
                "description": "AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)]", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }, 
            {
                "description": "AUC (0 - 48)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to 48h", 
                "measure": "Area Under the Curve From Time Zero 48 hours[AUC (0 - 48)]", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 56, 64, 72, 84, 96, 108, 120, 132, 144, 156, 216, 312 post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Amount of drug excreted unchanged in urine over 48 hours", 
                "measure": "Urinary Ae48", 
                "safety_issue": "No", 
                "time_frame": "0-24, 24-48 post dose"
            }, 
            {
                "description": "% of drug excreted unchanged in urine over 48 hours", 
                "measure": "Urinary AE48 (% excreted)", 
                "safety_issue": "No", 
                "time_frame": "0-24, 24-48 post dose"
            }, 
            {
                "measure": "Urinary CLR", 
                "safety_issue": "No", 
                "time_frame": "0-24, 24-48 post dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}